Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Successful meropenem desensitization in a patient with cystic fibrosis.

Wilson DL, Owens RC Jr, Zuckerman JB.

Ann Pharmacother. 2003 Oct;37(10):1424-8.

PMID:
14519038
2.

Antibiotic desensitization in adults with cystic fibrosis.

Burrows JA, Toon M, Bell SC.

Respirology. 2003 Sep;8(3):359-64.

PMID:
12911831
3.

Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.

Conway SP, Brownlee KG, Denton M, Peckham DG.

Am J Respir Med. 2003;2(4):321-32. Review.

PMID:
14719998
5.
6.

Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000).

Mendes C, Turner PJ; MYSTIC Study Group (Europe).

Diagn Microbiol Infect Dis. 2001 Dec;41(4):191-6.

PMID:
11777658
7.

Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia.

Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE.

Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1206-12.

PMID:
10764313
8.

Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy.

Weidmann A, Webb AK, Dodd ME, Jones AM.

J Cyst Fibros. 2008 Sep;7(5):409-11. doi: 10.1016/j.jcf.2008.02.005. Epub 2008 Mar 19.

9.
10.

The treatment of pulmonary infection in cystic fibrosis.

Webb AK.

Scand J Infect Dis Suppl. 1995;96:24-7. Review.

PMID:
7652499
11.

Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center.

Campana S, Taccetti G, Ravenni N, Masi I, Audino S, Sisi B, Repetto T, Döring G, de Martino M.

J Cyst Fibros. 2004 Aug;3(3):159-63.

13.
14.

Temocillin and cystic fibrosis: outcome of intravenous administration in patients infected with Pseudomonas cepacia.

Taylor RF, Gaya H, Hodson ME.

J Antimicrob Chemother. 1992 Mar;29(3):341-4.

PMID:
1375595
16.

Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis.

Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M.

J Cyst Fibros. 2008 Mar;7(2):142-6. Epub 2007 Sep 4.

17.

Risk factors for Burkholderia cepacia complex colonization and infection among patients with cystic fibrosis.

Walsh NM, Casano AA, Manangan LP, Sinkowitz-Cochran RL, Jarvis WR.

J Pediatr. 2002 Oct;141(4):512-7.

PMID:
12378190
19.

Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins.

Atanasković-Marković M, Gaeta F, Medjo B, Viola M, Nestorović B, Romano A.

Allergy. 2008 Feb;63(2):237-40. doi: 10.1111/j.1398-9995.2007.01532.x.

20.

Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.

Moriarty TF, McElnay JC, Elborn JS, Tunney MM.

Pediatr Pulmonol. 2007 Nov;42(11):1008-17.

PMID:
17902147

Supplemental Content

Support Center